Intellia Therapeutics Inc
Most Recent
CRISPR Therapeutics: Analysts’ View in November
On November 9, CRISPR Therapeutics’ (CRSP) stock price closed at $36.37, which is an ~3.53% decline from its close of $37.70 on November 8.
A Financial Overview of Intellia Therapeutics in September
In the second quarter, Intellia Therapeutics (NTLA) reported collaboration revenue of $7.7 million.
How CRISPR Therapeutics Is Positioned in September
CRISPR Therapeutics (CRSP) reported net collaboration revenues of $1.1 million in the second quarter of 2018 compared to $3.6 million in the second quarter of 2017.
CRISPR, Intellia, and Caribou Receive a US Genome-Editing Patent
On June 19, the co-owners of intellectual property associated with CRISPR-Cas9 genome editing technology were granted a US patent.
Why Editas Medicine Fell 7.8% on Monday
On June 11, Editas Medicine (EDIT) stock fell 7.8% over concerns that CRISPR CAS-9 Gene Therapy causes cancer.
Intellia Therapeutics Stock Fell 9.8% on Monday
On June 11, Intellia stock fell 9.8% to close at $24.56 over concerns of the CRISPR-CAS9 Gene Therapy.
Crispr Therapeutics Stock Fell 12.6% on June 11
On June 11, Crispr Therapeutics (CRSP) stock fell 12.6% to $59.57 over concerns that the CRISPR-CAS9 Gene Therapy causes cancer.